Skip to content

Study · Randomized controlled trial · n = 15 · 2005

2 results

Oxytocin modulates neural circuitry for social cognition and fear in humans.

Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A

The Journal of neuroscience : the official journal of the Society for Neuroscience1 Dec 2005Cited by 1,030 (Europe PMC)

PMID16339042 (opens in a new tab)PMCIDPMC6725903 (opens in a new tab)DOI10.1523/jneurosci.3984-05.2005 (opens in a new tab)PepBankPUB-16339042
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In healthy males, intranasal oxytocin reduced amygdala activation by fear-inducing visual stimuli compared with placebo.

    In plain wordsIn healthy men, nasal oxytocin lowered brain activity in the amygdala during fear-inducing pictures more than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseAmygdala activation by fear-inducing visual stimuli
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin potently reduced activation of the amygdala
    1 context sentence
    Summary · context
    We used functional magnetic resonance imaging to image amygdala activation by fear-inducing visual stimuli in 15 healthy males after double-blind crossover intranasal application of placebo or oxytocin.
  2. 02HumanRandomized controlled trialMechanism

    In healthy males, intranasal oxytocin reduced coupling of the amygdala to brainstem regions implicated in autonomic and behavioral manifestations of fear compared with placebo.

    In plain wordsIn healthy men, nasal oxytocin reduced the link between the amygdala and brainstem fear regions more than placebo.

    Peptide
    Oxytocin
    Outcome
    DecreaseCoupling of amygdala to brainstem regions
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Brain and neuronal activity · Nervous system and cognition
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    Compared with placebo, oxytocin potently reduced activation of the amygdala and reduced coupling of the amygdala to brainstem regions implicated in autonomic and behavioral manifestations of fear.
    1 context sentence
    Summary · context
    We used functional magnetic resonance imaging to image amygdala activation by fear-inducing visual stimuli in 15 healthy males after double-blind crossover intranasal application of placebo or oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedEarly phase 1NCT03211013

Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD

Palo Alto Veterans Institute for Researchn = 1710 Jul 2017 to 9 Jun 2021

Posttraumatic Stress Disorder

Trial pageClinicalTrials.govUpdated 10 Jun 2021
CompletedPhase 1Results postedNCT01834261

Brain Dynamics of Oxytocin

Stony Brook Universityn = 51Apr 2013 to May 2015

Brain Dynamics in Healthy Adults

Trial pageClinicalTrials.govUpdated 17 Mar 2017
Status unknownNot applicableNCT01039766

The Efficacy of a Single Dose of Intranasal Oxytocin in the Prevention of Post Traumatic Stress Disorder (PTSD)

Sheba Medical Centern = 24Feb 2010 to est. Jun 2011

Stress Disorders, Post-Traumatic

Trial pageClinicalTrials.govUpdated 9 Feb 2010

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.